Global Respiratory Care Devices Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Function (Diagnosis, Treatment, Monitoring), By Device Type (Ventilator, Spirometer, Pulse Oximeter, Inhaler, Nebulizer, Others), By Indication (COPD, Asthma, Sleep Apnea, Infectious Disease, Others), By End User (Hospitals, Ambulatory Care Center, Home Healthcare Setting), And By Geography- Forecasts From 2022 To 2027

  • Published : Aug 2022
  • Report Code : KSI061613458
  • Pages : 114

The global respiratory care devices market is projected to grow at a CAGR of 4.11% to reach US$12.781 billion by 2027, from US$10.035 billion in 2021.

The growing popularity of home healthcare is propelling the market demand in the forecast period. This is further supported by the growing geriatric population, which will bolster the market demand over the next five years. The prevalence of chronic obstructive pulmonary disease (COPD) is driving the market demand. Smoking is considered to be an underlying cause of the disease. The rising cases of premature births are further providing an impetus for the market to grow at a significant pace owing to the growing number of neonatal deaths due to respiratory diseases. With the growing demand for ventilators, at present, the market is projected to surge due to the growing number of cases of coronavirus patients at the global level.

Advancing technologies have enabled market players to develop intelligent ventilation solutions for patients with acute or chronic respiratory disorders as a result of technology improvements. The most advanced intelligent ventilation offerings are capable of automatically regulating ventilation and oxygenation in accordance with the goals specified by the doctors and the patient's physiologic inputs. Such inventions provide an opportunity for the market to grow at a significant pace generating high revenues due to their ease of operation.

Geographically, the North American region is estimated to hold a larger market share due to the high prevalence of chronic respiratory diseases such as COPD. Additionally, the high health expenditure is further augmenting the market growth in the forecast period. The Asia-Pacific region is said to be the fastest-growing region with a high prevalence of chronic diseases requiring assisted breathing. Also, Japan, in the APAC region, holds the highest number of elderly people in the world; this is further augmenting the market demand in the forecast period.

The rising incidences of preterm births are propelling the market demand in the forecast period.

Neonatal respiratory diseases are common in premature births. These diseases are defined as breathing disorders affecting newborns. Newborns born before 32 weeks of pregnancy are commonly susceptible to respiratory disorders because of the fact that their lungs are not able to make sufficient surfactant, which is a foamy substance that helps in keeping the lungs in full expansion. The most common neonatal respiratory disease includes apnea of prematurity, bronchopulmonary dysplasia, and pneumonia, among others. According to WHO estimates, around 15 million babies are born before 37 weeks of gestation, and the number of preterm births is rising. The mortality rates due to premature birth complications (which include respiratory diseases as well) are also rising. In order to avoid maximum preterm deaths, it is essential to strengthen the medical facilities, create a need for the manufacturing of state-of-the-art respiratory care devices for neonates, and provide a huge market opportunity with high market demand in the forecast period.

Over 60% of premature births take place in the African and South Asian regions. It is noted that the prevalence of premature births is higher in low (12%) and middle-income countries in comparison to high-income countries, which is only 9% (source: WHO, 2018).

The prevalence of COPD is further augmenting the market growth in the forecast period.

Chronic obstructive pulmonary disease (COPD), a group of diseases causing air-flow blockage and breathing problems, is quite prevalent worldwide. Currently, COPD has no cure, but it can be treated. As per WHO estimates, the global burden of disease study reported that COPD was prevalent in around 251 million individuals in 2016 at the global level. Around 3.5 million deaths were caused in 2015. It was also noted that the maximum (more than 90%) prevalence of deaths by COPD took place in low and middle-income countries. The major factors affecting individuals with COPD are active and passive smoking. Hence, with the presence of smoking at the international level, market growth is expected to fuel the growing number of affected individuals. Also, COPD is found to be prevalent among the geriatric population. Hence, with the increasing geriatric population in the world, the market is projected to surge at a rapid pace.

According to the World Health Organization (WHO), by 2050, the population aged 60 and above worldwide is estimated to attain a population size of 2 billion, up from a population size of 900 million in 2015. The pace of population ageing is much faster in comparison to the past. This has given rise to increasing healthcare costs required for the treatment of non-communicable age-associated diseases. Japan from the Asia-Pacific region has the maximum geriatric population worldwide, followed by Italy. Population ageing and growth at advanced stages, above 65 years of age, has further risen to concerns such as the pressure on health systems that need to adapt in order to meet the growing demands for care, services, and technologies for the prevention and treatment of age-associated chronic diseases. Thus, propelling the market’s growth during the forecast period. Other risk factors for COPD include indoor and outdoor pollution, as well as occupational dust and chemicals. 

The presence of stringent regulations for the approval of medical devices is restraining the market growth in the forecast period.

As per the procedure-related risks associated, medical devices are categorized into categories or classes of medical devices on the basis of the risks associated. All medical devices are required to pass through certain phases during their life. These steps include conception and development, manufacturing, packaging and labelling, and advertising, among others. These steps involve undergoing certain checkpoints, failing which would lead to the disqualification of the product. Additionally, misleading or fraudulent advertisements may tend to increase sales, but the buyer may experience a loss of money and reputation as it may harm the patient or the user. Therefore, strict regulations provide protection against such fraudulent cases, and this poses a threat to hampering the market’s growth due to the rejection of medical devices resulting in disqualification for further use.

In the case of high-risk devices, medical devices categorized under Class III, FDA has determined that the general and special controls alone are not sufficient to provide assurance that these Class III devices are safe. Hence, these devices are required to fill in a premarket approval application to obtain marketing approval. However, respiratory devices are classified under device class II and require FDA review through premarket notification 510 (k).

Key Developments in the Market

  • In March 2022, Magnet Group and Koko, LLC entered into a partnership. According to the agreement, the partnership will last till September 2024. Through this partnership, the former can access the latter's gold-standard pulmonary and respiratory testing products portfolio and offer better offerings.
  • In February 2022, AstraZeneca collaborated with Honeywell to develop innovative respiratory inhales by leveraging the HFO-1234ZE, which can effectively cause 99.99% less GWP (Global Warming Potential) when compared to current respiratory medicines.
  • In November 2021, US-based Quipt Home Medical Corp., a leading home medical equipment industry, announced the acquisition of a Southeastern US-based private Biomedical Services firm with an annual net income of $225,000. Ventilators, oxygen devices, CPAP/bilevel devices, and other respiratory equipment are among the many respiratory products that are serviced by the acquisition. This covers equipment from the home and hospital contexts, as well as from acute and non-acute settings. With this acquisition, the company is putting its emphasis on providing outstanding patient care and safety and is able to strengthen its partnerships with new and existing long-term care institutions, hospital systems, and other medical facilities around the nation.

COVID-19 Impact on Respiratory Care Devices Market

COVID-19 had a positive impact on the global respiratory care devices market. The exponential surge in active cases has drastically increased the demand for respiratory care devices. Subsequently, to meet the increased demand, multiple market players upscaled their production and developed new offerings. For instance, in March 2020, GE Healthcare and Ford Motor teamed up to rapidly produce 50,000 ventilators within 100 days in their Michigan facility to meet the demand. On a similar note, in April 2020, Telsa joined a group of automakers to produce ventilators using automobile parts and pledged to offer resources and donate supplies to produce more ventilators. Similar developments caused the market size for respiratory care devices to increase amid the pandemic.

Global Respiratory Care Devices Market Scope:

Report Metric Details
 Market Size Value in 2021  US$10.035 billion
 Market Size Value in 2027  US$12.781 billion
 Growth Rate  CAGR of 4.11% from 2021 to 2027
 Base Year  2021
 Forecast Period  2022–2027
 Forecast Unit (Value)  USD Billion
 Segments Covered  Function, Device Type, Indication, End User, And Geography
 Regions Covered  North America, South America, Europe, Middle East and Africa, Asia Pacific
 Companies Covered Koninklijke Philips N.V., ResMed, Medtronic, Masimo, Fisher & Paykel Healthcare Limited, Getinge AB, Air Liquide Medical Systems, Drägerwerk AG & Co. KGaA, Hamilton Medical, Invacare Corporation
 Customization Scope  Free report customization with purchase



  • By Function
    • Diagnosis
    • Treatment
    • Monitoring
  • By Device Type
    • Ventilator
    • Spirometer
    • Pulse Oximeter
    • Inhaler
    • Nebulizer
    • Others
  • By Indication
    • COPD
    • Asthma
    • Sleep Apnea
    • Infectious Disease
    • Others
  • By End User
    • Hospitals
    • Ambulatory Care Center
    • Home Healthcare Setting
  • By Geography
    • North America
      • USA
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • UK
      • Germany
      • France
      • Spain
      • Italy
      • Others
    • Middle East and Africa
      • UAE
      • Israel
      • Saudi Arabia
      • Others
    • Asia Pacific
      • Japan
      • China
      • India
      • Australia
      • Indonesia
      • Thailand
      • Others

Frequently Asked Questions (FAQs)

Q1. What will be the respiratory care devices market size by 2027?
A1. The global respiratory care devices market is projected to reach a market size of US$12.781 billion in 2027. 

Q2. What is the size of the global respiratory care devices market?
A2. Respiratory Care Devices Market was valued at US$10.035 billion in 2021. 

Q3. What are the growth prospects for the respiratory care devices market?
A3. The respiratory care devices market is projected to grow at a CAGR of 4.11% over the forecast period. 

Q4. Which region holds the maximum market share of the respiratory care devices market?
A4. Geographically, the North American region is estimated to hold a larger share of the respiratory care devices market due to the high prevalence of chronic respiratory diseases such as COPD.

Q5. What factors are anticipated to drive the respiratory care devices market growth?
A5. The growing popularity of home healthcare is propelling the respiratory care devices market demand in the forecast period.


1.1. Market Overview
1.2. COVID-19 Scenario
1.3. Market Definition
1.4. Market Segmentation

2.1. Research Data
2.2. Assumptions

3.1. Research Highlights

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Force Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5.1. Introduction
5.2. Diagnosis
5.3. Treatment
5.4. Monitoring

6.1. Introduction
6.2. Ventilator
6.3. Spirometer
6.4. Pulse Oximeter
6.5. Inhaler
6.6. Nebulizer
6.7. Others

7.1. Introduction
7.2. COPD
7.3. Asthma
7.4. Sleep Apnea
7.5. Infectious Disease
7.6. Others

8.1. Introduction
8.2. Hospitals
8.3. Ambulatory Care Center
8.4. Home Healthcare Setting

9.1. Introduction
9.2. North America
9.2.1. United States
9.2.2. Canada
9.2.3. Mexico
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Others
9.4. Europe
9.4.1. UK
9.4.2. Germany
9.4.3. France
9.4.4. Spain
9.4.5. Italy
9.4.6. Others
9.5. Middle East and Africa
9.5.1. United Arab Emirates
9.5.2. Israel
9.5.3. Saudi Arabia
9.5.4. Others
9.6. Asia Pacific
9.6.1. Japan
9.6.2. China
9.6.3. India
9.6.4. Australia
9.6.5. Indonesia
9.6.6. Thailand
9.6.7. Others

10.1. Major Players and Strategy Analysis
10.2. Emerging Players and Market Lucrativeness
10.3. Mergers, Acquisitions, Agreements, and Collaborations
10.4. Vendor Competitiveness Matrix

11.1. Koninklijke Philips N.V.
11.2. ResMed
11.3. Medtronic
11.4. Masimo
11.5. Fisher & Paykel Healthcare Limited
11.6. Getinge AB
11.7. Air Liquide Medical Systems
11.8. Drägerwerk AG & Co. KGaA
11.9. Hamilton Medical
11.10. Invacare Corporation

Koninklijke Philips N.V.




Fisher & Paykel Healthcare Limited

Getinge AB

Air Liquide Medical Systems

Drägerwerk AG & Co. KGaA

Hamilton Medical

Invacare Corporation